EXEL

SEC source: 0000939767-21-000111 · wf-form4_163979079438564.xml · nonDerivative · entry 1

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 588,208

F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award under the Exelixis, Inc. 2017 Equity Incentive Plan covering 9,994 shares of common stock. The PSU award generally vests as follows: (i) 50% of the original number of shares subject to the award vest upon certification by the Compensation Committee (the "Committee") that Exelixis, Inc. has achieved certain performance criteria related to the submission of Investigational New Drug applications with the U.S. Food and Drug Administration, or equivalent applications or filings with a foreign governmental authority, with respect to product candidates discovered, in-licensed or acquired by Exelixis, Inc. (the "2018 PSU Goal"); and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification.

F3 · shares: On December 15, 2021, the Committee convened to determine that the 2018 PSU Goal had been achieved, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on February 15, 2023, subject to the Reporting Person's continuous service through that date.

F4 · balance_after: Includes 108,812 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000117 · wf-form4_163979168754039.xml · nonDerivative · entry 2

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 1,235,313

F1 · kind: On November 29, 2021, the Reporting Person gifted 196,524 shares of Exelixis, Inc. common stock to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended.

F3 · ownership.nature: Shares held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended.

SEC source: 0000939767-21-000117 · wf-form4_163979168754039.xml · nonDerivative · entry 1

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,764

F1 · kind: On November 29, 2021, the Reporting Person gifted 196,524 shares of Exelixis, Inc. common stock to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended.

F2 · balance_after: Includes 170,764 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000106 · wf-form4_163797353673102.xml · nonDerivative · entry 1

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,802

F1 · balance_after: Includes 132,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000105 · wf-form4_163771629639082.xml · derivative · entry 3

FELDBAUM CARL B · CIK 0001326377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2022-05-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 28, 2015.

SEC source: 0000939767-21-000105 · wf-form4_163771629639082.xml · nonDerivative · entry 2

FELDBAUM CARL B · CIK 0001326377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,521

F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.57 to $17.68. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4.

SEC source: 0000939767-21-000105 · wf-form4_163771629639082.xml · nonDerivative · entry 1

FELDBAUM CARL B · CIK 0001326377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,521

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-21-000104 · wf-form4_163719962398845.xml · nonDerivative · entry 3

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 255,038

F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 20, 2019, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on October 22, 2020.

SEC source: 0000939767-21-000104 · wf-form4_163719962398845.xml · nonDerivative · entry 2

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 299,222

F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved the performance goal on September 2, 2020.

SEC source: 0000939767-21-000104 · wf-form4_163719962398845.xml · nonDerivative · entry 1

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,205

F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded on October 3, 2017.

F2 · balance_after: Includes 132,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000103 · wf-form4_163719952051824.xml · nonDerivative · entry 3

Senner Christopher J. · CIK 0001648367 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 357,815

F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 20, 2019, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on October 22, 2020.

SEC source: 0000939767-21-000103 · wf-form4_163719952051824.xml · nonDerivative · entry 2

Senner Christopher J. · CIK 0001648367 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 404,735

F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved the performance goal on September 2, 2020.

SEC source: 0000939767-21-000103 · wf-form4_163719952051824.xml · nonDerivative · entry 1

Senner Christopher J. · CIK 0001648367 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 407,301

F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded on October 3, 2017.

F2 · balance_after: Includes 115,013 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000102 · wf-form4_163719943844326.xml · nonDerivative · entry 3

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 578,214

F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 20, 2019, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on October 22, 2020.

SEC source: 0000939767-21-000102 · wf-form4_163719943844326.xml · nonDerivative · entry 2

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 624,957

F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved the performance goal on September 2, 2020.

SEC source: 0000939767-21-000102 · wf-form4_163719943844326.xml · nonDerivative · entry 1

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 626,268

F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded on October 3, 2017.

F2 · balance_after: Includes 103,815 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000101 · wf-form4_163719916632747.xml · nonDerivative · entry 3

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 367,288

F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 20, 2019, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on October 22, 2020.

SEC source: 0000939767-21-000101 · wf-form4_163719916632747.xml · nonDerivative · entry 2

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 544,420

F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved the performance goal on September 2, 2020.

SEC source: 0000939767-21-000101 · wf-form4_163719916632747.xml · nonDerivative · entry 1

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 550,538

F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded on October 3, 2017.

F2 · balance_after: Includes 170,764 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000100 · wf-form4_163719731783522.xml · derivative · entry 7

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,500

Underlying: Common Stock · 47,500 shares

Expires 2022-09-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The option, representing the right to purchase a total of 190,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 16, 2019.

SEC source: 0000939767-21-000100 · wf-form4_163719731783522.xml · nonDerivative · entry 5

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 349,077

F6 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 20, 2019, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on October 22, 2020.

SEC source: 0000939767-21-000100 · wf-form4_163719731783522.xml · nonDerivative · entry 4

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 402,099

F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved the performance goal on September 2, 2020.

SEC source: 0000939767-21-000100 · wf-form4_163719731783522.xml · nonDerivative · entry 3

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 404,422

F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded on October 3, 2017.

SEC source: 0000939767-21-000100 · wf-form4_163719731783522.xml · nonDerivative · entry 2

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 411,240

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2021.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.94 to $18.28. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-21-000100 · wf-form4_163719731783522.xml · nonDerivative · entry 1

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 458,740

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 104,202 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000098 · wf-form4_163598474276526.xml · nonDerivative · entry 1

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 632,825

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2020.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.00 to $22.06. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

F3 · balance_after: Includes 207,930 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000091 · wf-form4_163494838598490.xml · nonDerivative · entry 2

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 561,068

F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on October 22, 2021.

SEC source: 0000939767-21-000091 · wf-form4_163494838598490.xml · nonDerivative · entry 1

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 585,815

F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: On October 22, 2020, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 188,005 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the Target Shares vest upon the Committee's certification of achievement of certain performance criteria as certified by the Compensation Committee (the "Committee"); and (ii) 50% of the Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU.

F3 · shares: The Committee determined that certain performance criteria had been achieved, effective October 22, 2021, resulting in the Reporting Person's eligibility to vest up to 50% of the Target Shares subject to the PSU. Accordingly, the Committee's certification resulted in the immediate vesting of 25% of the Target Shares, and 25% of the Target Shares will vest on November 15, 2022, subject to the Reporting Person's continuous service through that date. The Reporting Person remains eligible for additional vesting depending the level and timing of achievement of the performance criteria through December 31, 2024.

F4 · balance_after: Includes 538,814 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000089 · wf-form4_163434332005821.xml · derivative · entry 4

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,000

Underlying: Common Stock · 47,500 shares

Expires 2022-09-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 190,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 16, 2019.

SEC source: 0000939767-21-000089 · wf-form4_163434332005821.xml · nonDerivative · entry 2

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 411,240

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2021.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.69 to $22.07. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-21-000089 · wf-form4_163434332005821.xml · nonDerivative · entry 1

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 458,740

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 229,577 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000088 · wf-form4_163434323702285.xml · nonDerivative · entry 1

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 637,942

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2020.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.00 to $22.07. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

F3 · balance_after: Includes 207,930 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000087 · wf-form4_163339281116981.xml · nonDerivative · entry 2

Senner Christopher J. · CIK 0001648367 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 415,528

F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 30, 2021.

SEC source: 0000939767-21-000087 · wf-form4_163339281116981.xml · nonDerivative · entry 1

Senner Christopher J. · CIK 0001648367 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 424,101

F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: On September 11, 2020, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 65,135 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the Target Shares vest upon certification by the Compensation Committee (the "Committee") that Exelixis has achieved certain performance criteria; and (ii) 50% of the Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU.

F3 · shares: On September 30, 2021, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 50% of the Target Shares subject to the PSU. Accordingly, the Committee's certification resulted in the immediate vesting of 25% of the Target Shares, and 25% of the Target Shares will vest on November 15, 2022, subject to the Reporting Person's continuous service through that date. The Reporting Person remains eligible for additional vesting depending the level and timing of achievement of the performance criteria through December 31, 2024.

F4 · balance_after: Includes 224,627 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000086 · wf-form4_163339274187742.xml · nonDerivative · entry 2

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 650,825

F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 30, 2021.

SEC source: 0000939767-21-000086 · wf-form4_163339274187742.xml · nonDerivative · entry 1

Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 658,418

F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: On September 11, 2020, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 57,900 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the Target Shares vest upon certification by the Compensation Committee (the "Committee") that Exelixis has achieved certain performance criteria; and (ii) 50% of the Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU.

F3 · shares: On September 30, 2021, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 50% of the Target Shares subject to the PSU. Accordingly, the Committee's certification resulted in the immediate vesting of 25% of the Target Shares, and 25% of the Target Shares will vest on November 15, 2022, subject to the Reporting Person's continuous service through that date. The Reporting Person remains eligible for additional vesting depending the level and timing of achievement of the performance criteria through December 31, 2024.

F4 · balance_after: Includes 207,930 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,220 shares of common stock acquired on April 30, 2021, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan.

SEC source: 0000939767-21-000085 · wf-form4_163339247902642.xml · nonDerivative · entry 2

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 304,528

F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 30, 2021.

SEC source: 0000939767-21-000085 · wf-form4_163339247902642.xml · nonDerivative · entry 1

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 309,944

F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: On September 11, 2020, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 57,900 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the Target Shares vest upon certification by the Compensation Committee (the "Committee") that Exelixis has achieved certain performance criteria; and (ii) 50% of the Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU.

F3 · shares: On September 30, 2021, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 50% of the Target Shares subject to the PSU. Accordingly, the Committee's certification resulted in the immediate vesting of 25% of the Target Shares, and 25% of the Target Shares will vest on November 15, 2022, subject to the Reporting Person's continuous service through that date. The Reporting Person remains eligible for additional vesting depending the level and timing of achievement of the performance criteria through December 31, 2024.

F4 · balance_after: Includes 236,115 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000084 · wf-form4_163339215355376.xml · nonDerivative · entry 2

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 411,240

F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 30, 2021.

SEC source: 0000939767-21-000084 · wf-form4_163339215355376.xml · nonDerivative · entry 1

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 418,417

F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: On September 11, 2020, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 57,900 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the Target Shares vest upon certification by the Compensation Committee (the "Committee") that Exelixis has achieved certain performance criteria; and (ii) 50% of the Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU.

F3 · shares: On September 30, 2021, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 50% of the Target Shares subject to the PSU. Accordingly, the Committee's certification resulted in the immediate vesting of 25% of the Target Shares, and 25% of the Target Shares will vest on November 15, 2022, subject to the Reporting Person's continuous service through that date. The Reporting Person remains eligible for additional vesting depending the level and timing of achievement of the performance criteria through December 31, 2024.

F4 · balance_after: Includes 229,577 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000083 · wf-form4_163244255527325.xml · derivative · entry 4

Senner Christopher J. · CIK 0001648367 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 90,000 shares

Expires 2022-07-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option, representing the right to purchase a total of 350,000 shares of Common Stock, became fully exercisable on July 15, 2019.

SEC source: 0000939767-21-000083 · wf-form4_163244255527325.xml · nonDerivative · entry 2

Senner Christopher J. · CIK 0001648367 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 391,534

F2 · kind: Represents a "net exercise" of an outstanding stock option. The Reporting Person received 34,943 shares of Common Stock on the net exercise of a stock option to purchase 90,000 shares of Common Stock. The Issuer withheld 55,057 shares of Common Stock underlying the stock option for payment of the exercise price and tax withholding using a stock price on September 21, 2021 of $20.33.

SEC source: 0000939767-21-000083 · wf-form4_163244255527325.xml · nonDerivative · entry 1

Senner Christopher J. · CIK 0001648367 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 446,591

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 208,343 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000082 · wf-form4_163192306597853.xml · derivative · entry 5

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2021-09-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 120,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.

SEC source: 0000939767-21-000082 · wf-form4_163192306597853.xml · nonDerivative · entry 2

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,994

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2021.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.14 to $20.52. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-21-000082 · wf-form4_163192306597853.xml · nonDerivative · entry 1

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 305,994

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 221,640 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000081 · wf-form4_163192296573118.xml · derivative · entry 4

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,500

Underlying: Common Stock · 47,500 shares

Expires 2022-09-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 190,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 16, 2019.

SEC source: 0000939767-21-000081 · wf-form4_163192296573118.xml · nonDerivative · entry 2

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 389,467

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2021.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.62. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-21-000081 · wf-form4_163192296573118.xml · nonDerivative · entry 1

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 436,967

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 215,102 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000079 · wf-form4_162933099603526.xml · derivative · entry 4

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 55,000 shares

Expires 2022-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 175,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.